Drug Profile
Research programme: PRL-3-targeting agents - Sanofi
Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Class Small molecules
- Mechanism of Action Phosphoric monoester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer metastases
Most Recent Events
- 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
- 23 Apr 2004 This programme is still in active development - 95th Annual Meeting of the American Association for Cancer Research (AACR-2004)
- 02 Apr 2002 Preclinical trials in Cancer metastases in USA (unspecified route)